Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.24 USD
Change Today +0.03 / 0.48%
Volume 7.6K
As of 1:41 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - $8.40
52 Week Low
01/12/15 - $5.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

columbia laboratories inc (CBRX) Related Businessweek News

No Related Businessweek News Found

columbia laboratories inc (CBRX) Details

Columbia Laboratories, Inc., together with its subsidiaries, develops, manufactures, licenses, and sells pharmaceutical products. It operates through two segments, Product and Service. The company offers CRINONE, a progesterone gel for use in infertility. It also provides pharmaceutical development services, clinical trial manufacturing services, and analytical and consulting services to the pharmaceutical industry. The company operates in the United States, Switzerland, and internationally. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

85 Employees
Last Reported Date: 03/18/15
Founded in 1986

columbia laboratories inc (CBRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Director and Chief Executive Officer of Molec...
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories Inc. Licenses Worldwide Rights to a Novel Intra-Vaginal Ring Technology

Columbia Laboratories Inc. has licensed worldwide rights to a novel intra-vaginal ring technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring. Columbia has agreed to minimum annual expenditures to develop products using the vaginal ring technology, and will make milestone-based payments to MGH/MIT when various stages of product development and commercialization are achieved. The Company will also share a portion of any royalties or sublicense revenues received from products utilizing the segmented IVR technology with MGH and MIT.

Columbia Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015; Restates Revenue Results for the First Three Quarters of 2014

Columbia Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014.  For the quarter, revenues were $7.3 million, as compared with $7.8 million in the year-ago period.  The decrease resulted largely from the deferral of expected services projects from the 2014 fourth quarter into 2015. This decline was offset in part by a $1.0 million increase in product revenues as compared to 2013.  The reduction in anticipated revenue lowered gross margin for the quarter as compared to the prior year quarter.  Operating income was $0.3 million compared to operating income of $0.8 million in the fourth quarter of 2013. Income before income taxes was $0.4 million compared to $1.1 million in the fourth quarter of 2013. The company recorded net loss of $0.5 million, or $0.05 per basic and diluted share, in the fourth quarter of 2014 compared to net income of $1.1 million, or $0.06 per diluted share, in the same period of 2013. Non-GAAP adjusted EBITDA was $1.1 million compared to $1.7 million last year. Cash flow from operations generated was $1.0 million. For the year 2014, revenues increased 11% year-over-year to $32.5 million as compared to $29.2 million in the previous year. The increase is driven by the full-year contribution of the diversified revenue stream of Columbia's service business, offsetting a temporary decline in product revenues from Merck Serono caused by a routine marketing license renewal for CRINONE® (progesterone gel) in a large market.  Income from operations was $3.8 million against $5.9 million last year. Income before income taxes was $4.4 million compared to $6.7 million last year. The company recorded net income of $3.4 million, or $0.27 per diluted share. The result compares with net income of $6.7 million, or $0.52 per diluted share, for the year ended December 31, 2013.  Non-GAAP adjusted EBITDA was $7.0 million compared to $9.5 million for the 2013 period, which included a non-recurring adjustment of $1.6 million related to the acquisition of the services business in September 2013. Cash flow from operations generated was $6.9 million. The company expects low double-digit total net revenue growth for the full year of 2015. In its Form 10-K filed on March 18, 2015 with the U.S. Securities and Exchange Commission, the company reported the revision of the consolidated interim financial statements, as well as quarterly financial data, for the first three quarters of 2014. Full year of 2014 results are unaffected by the revisions.  These revisions had the cumulative effect of reducing the company's previously reported total revenues during the first three quarters of 2014 by $0.4 million, from $25.6 million to $25.2 million.  After thorough analysis, the company determined that the previously issued financial statements could continue to be relied upon and are representative of the performance during that time period.

United States District Court for the District of New Jersey Dismisses the Securities Class Action Lawsuit Against Columbia Laboratories Inc. and Watson Pharmaceuticals, Inc

Columbia Laboratories Inc. announced that the United States Court of Appeals for the Third Circuit affirmed the prior decision of the United States District Court for the District of New Jersey dismissing the securities class action lawsuit, entitled In re Columbia Laboratories Inc., Securities Litigation, (D.C. No. 2-12-cv-00614) filed against Columbia, Watson Pharmaceuticals, Inc, and various Columbia and Watson executives.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $6.24 USD +0.03

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.62 USD -0.71
View Industry Companies

Industry Analysis


Industry Average

Valuation CBRX Industry Range
Price/Earnings 20.0x
Price/Sales 2.0x
Price/Book 1.6x
Price/Cash Flow 19.5x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at